Skip to content

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03516656
Enrollment
20
Registered
2018-05-04
Start date
2018-03-23
Completion date
2021-08-24
Last updated
2023-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism

Brief summary

The purpose of this study is to determine if weight-based heparin infusions at a rate of 10 units/kg/hour are sufficient to maintain a target anti-Xa of 0.1-0.35 IU/mL for VTE prophylaxis in patients undergoing microvascular surgery. Additionally, a pilot protocol has been developed to titrate these heparin infusions to ensure patients have sufficient VTE prophylaxis. All patients will be enrolled in the observational arm of the study and receive anti-Xa level monitoring. Patients with out-of-range anti-Xa levels will cross over to the interventional arm of the study and receive real time heparin infusion dose adjustments per the pilot protocol. The primary outcome measured will be the percentage of patients with anti-Xa levels in the target range of 0.1-0.35 IU/mL while on a heparin infusion at 10 units/kg/hour.

Interventions

Patients will be placed on heparin infusions per their surgeon's discretion.

Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.

Sponsors

University of Utah
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing surgical procedures * Initiation of a heparin infusion at a rate of 500 units/hour intraoperatively or postoperatively

Exclusion criteria

* Age \<18 years old * Pregnant * Incarcerated * Mentally disabled

Design outcomes

Primary

MeasureTime frame
Percentage of Anti-Xa Levels Within Target Range (0.1-0.35 IU/mL)Through study completion, an average of 1 year

Secondary

MeasureTime frame
Number of Rate AdjustmentsThrough study completion, an average of 1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026